A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 391 participants.
Also called NCT07700875
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 391 participants
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Registry
-
NCT07700875
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT07700875. Randomized; quadruple masking; primary purpose treatment. Start 2022-12-29 (actual); primary completion 2023-08-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- QR12000 Compound Tablets 75 mg
- Intervention (Drug)
- QR12000 Compound Tablets 75 mg placebo
- Intervention (Drug)
- QR12000 Compound Tablets 150 mg
- Intervention (Drug)
- QR12000 Compound Tablets 150 mg placebo
- Intervention (Drug)
- QR01019 potassium salt 50 mg
- Intervention (Drug)
- QR01019 potassium salt 50 mg placebo
- Intervention (Drug)
- Sacubitril / valsartan 200 mg
- Intervention (Drug)
- Sacubitril / valsartan 200 mg placebo
- Intervention (Drug)
- Valsartan 160 mg
- Intervention (Drug)
- Valsartan 160 mg placebo
- Lead sponsor
- Wuhan Createrna Science and Technology Co., Ltd
Record details
- Record id
cardio:ct-nct07700875- Content hash
2cdbb192fddf4d21050d2ce60b5b459b29934580cb0738270ce231f1b9fae8ef